ZA904842B - Novel methods of treatment using ranolazine and related piperazine derivatives - Google Patents

Novel methods of treatment using ranolazine and related piperazine derivatives

Info

Publication number
ZA904842B
ZA904842B ZA904842A ZA904842A ZA904842B ZA 904842 B ZA904842 B ZA 904842B ZA 904842 A ZA904842 A ZA 904842A ZA 904842 A ZA904842 A ZA 904842A ZA 904842 B ZA904842 B ZA 904842B
Authority
ZA
South Africa
Prior art keywords
treatment
ranolazine
piperazine derivatives
novel methods
related piperazine
Prior art date
Application number
ZA904842A
Other languages
English (en)
Inventor
Robert James Dow
James Dow Robert
Pierre Ferrandon
Ferrandon Pierre
Original Assignee
Syntex Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Pharma Ltd filed Critical Syntex Pharma Ltd
Publication of ZA904842B publication Critical patent/ZA904842B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ZA904842A 1989-06-23 1990-06-21 Novel methods of treatment using ranolazine and related piperazine derivatives ZA904842B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37043589A 1989-06-23 1989-06-23

Publications (1)

Publication Number Publication Date
ZA904842B true ZA904842B (en) 1992-02-26

Family

ID=23459660

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA904842A ZA904842B (en) 1989-06-23 1990-06-21 Novel methods of treatment using ranolazine and related piperazine derivatives

Country Status (13)

Country Link
US (2) US5506229A (da)
EP (3) EP0407780B1 (da)
JP (1) JP3232085B2 (da)
AT (3) ATE142497T1 (da)
AU (1) AU633589B2 (da)
CA (1) CA2019580C (da)
DE (3) DE69028457T2 (da)
DK (3) DK0714660T3 (da)
ES (3) ES2177601T3 (da)
GR (1) GR3020976T3 (da)
IE (1) IE80710B1 (da)
NZ (2) NZ247044A (da)
ZA (1) ZA904842B (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6711436B1 (en) 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
AU758370B2 (en) * 1997-08-08 2003-03-20 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
NZ520780A (en) * 2000-02-18 2006-04-28 Cv Therapeutics Inc Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
WO2001062711A2 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
AU2001238590A1 (en) * 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
NZ520782A (en) * 2000-02-22 2004-03-26 Cv Therapeutics Inc Substituted piperazine compounds that are partial fatty acid oxidation inhibitors
AU2001285245A1 (en) * 2000-08-25 2002-03-13 Organ Recovery Systems, Inc. Methods of thrombolytic organ treatment and repair
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0028414D0 (en) 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
ATE365737T1 (de) 2002-12-05 2007-07-15 Cv Therapeutics Inc Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren
NZ541069A (en) 2003-01-03 2008-09-26 Cv Therapeutics Inc Piperazine derivatives as fatty acid oxidation inhibitors
WO2004069818A1 (en) 2003-01-17 2004-08-19 Cv Therapeutics Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
CA2530376A1 (en) 2003-06-23 2005-01-06 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
CA2550257A1 (en) 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
US7271169B2 (en) * 2004-09-08 2007-09-18 Cv Therapeutics, Inc. Substituted heterocyclic compounds
MX2007005367A (es) * 2004-11-09 2007-06-18 Cv Therapeutics Inc Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca.
MX2007008162A (es) * 2005-01-06 2007-07-24 Cv Therapeutics Inc Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina.
US20060205727A1 (en) * 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
EP2117549A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
EP2515880B1 (en) 2009-05-28 2019-11-27 Lupin Limited Novel pharmaceutical compositions of ranolazine
AU2015200961B2 (en) * 2009-07-09 2017-02-16 Ozteo Pty Ltd Treatment of Non-Neuronal and Non-Cardiac Cell, Tissue and Organ Damage and Associated Pain with Persistent Sodium Current Blockers
EP2453893A4 (en) 2009-07-09 2012-06-20 Ozteo Pty Ltd TREATMENT OF NON-NEURONIC AND NON-MYOCARDIAL CELL, TISSUE, ORGANIC ANGER AND RELATED PAIN THROUGH PERMANENT SODIUM CHANNEL BLOCKERS
MX2012003362A (es) 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
CA2835293C (en) * 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
KR101476379B1 (ko) * 2011-11-30 2014-12-29 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
KR101331186B1 (ko) * 2013-08-05 2013-11-22 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
JP2024537585A (ja) * 2021-09-27 2024-10-16 タスリー・ファーマシューティカル・グループ・カンパニー・リミテッド 心筋虚血の治療のための医薬組成物及びその製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry

Also Published As

Publication number Publication date
EP0719558A1 (en) 1996-07-03
DE69034000T2 (de) 2003-06-05
EP0719558B1 (en) 2002-06-05
DE69028457D1 (de) 1996-10-17
DK0407780T3 (da) 1996-09-30
IE902250A1 (en) 1991-01-16
ES2091211T3 (es) 1996-11-01
ATE218344T1 (de) 2002-06-15
ATE223218T1 (de) 2002-09-15
ES2182863T3 (es) 2003-03-16
DE69034000D1 (de) 2002-10-10
US5506229A (en) 1996-04-09
DE69028457T2 (de) 1997-02-20
IE902250L (en) 1990-12-23
DE69033967D1 (de) 2002-07-11
CA2019580A1 (en) 1990-12-23
NZ234184A (en) 1997-01-29
AU633589B2 (en) 1993-02-04
JP3232085B2 (ja) 2001-11-26
AU5761890A (en) 1991-01-03
ES2177601T3 (es) 2002-12-16
EP0407780A2 (en) 1991-01-16
EP0407780B1 (en) 1996-09-11
CA2019580C (en) 2007-03-27
EP0714660B1 (en) 2002-09-04
EP0714660A1 (en) 1996-06-05
NZ247044A (en) 1997-04-24
DK0719558T3 (da) 2002-10-07
ATE142497T1 (de) 1996-09-15
DK0714660T3 (da) 2002-10-07
DE69033967T2 (de) 2002-12-19
GR3020976T3 (en) 1996-12-31
EP0407780A3 (en) 1992-01-02
JPH0348672A (ja) 1991-03-01
IE80710B1 (en) 1998-12-16
US5906988A (en) 1999-05-25

Similar Documents

Publication Publication Date Title
AU633589B2 (en) Novel methods of treatment using ranolazine and related piperazine derivatives
HU9301314D0 (en) Quinazoline derivatves for improving anto-tumouric activity
PL316613A1 (en) Novel derivatives of piperazine, methods of obtaining them and agents containing such derivatives
UA32429C2 (uk) Засіб для лікування нетримання сечі
DE58900119D1 (de) Chirurgisches instrument zum einsetzen von hueftpfannen-prothesen.
FI960416L (fi) Käsitellyt mineraalitäyteaineet, näitä täyteaineita ja polyoleja sisältävät suspensiot sekä näiden suspensioiden käyttö polymetaanivaahtojen valmistamiseksi
EP0251585A3 (en) Treatment of iron-containing subterranean formations
ATE103918T1 (de) 5,11-dihydro-6h-dipyrido(3,2-b:2',3'e>(1,4>diazepin-6-one und -thione und ihre verwendung bei der aids-vorbeugung oder behandlung.
GB2146527B (en) Use of benzothiophene derivatives as antiasthmatic agents
IT1240486B (it) Procedimento di ammollo enzimatico per pelli e pellami.
EP0299457A3 (en) Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome
GB9020441D0 (en) New method of treatment & heterocyclic compounds used therein
MY105128A (en) Bu-3608 derivatives.
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
ATE70181T1 (de) Verwendung von oxochinazolinderivaten bei der behandlung von hyperurikaemie.
IE902014L (en) Use of naftopidil for treating dysuric
DE3576498D1 (de) 2-sulfamoyl-1h-indole-derivate zur behandlung von hohem intraocularem druck.
GR3017350T3 (en) 2-Alkyl-3-benzoylbenzofurans useful for treating cardiac arrhythmia.
HU895658D0 (en) Equipment, well operating without extra energy for the purification of sewages soiling the environment and process therefor
DE69001988D1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
EP0376608A3 (en) Benzamide derivatives as antiarrhythmics
NO892044D0 (no) Fremgangsmaate og anlegg for behandling av borekaks.
YU184488A (en) Universal dynamic prosthesis for correcting, treating and static unburdoning of backbone area
CS235689A1 (en) Method of tungsten carbide containing wastes treatment
IE880360L (en) Treating hyperuricaemia